Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

Gualtiero Ricciardi, A Diamantopoulos, M Benucci, S Capri, W Berger, N Wintfeld, Giulio Giuliani

Risultato della ricerca: Contributo in rivistaArticolo in rivista

35 Citazioni (Scopus)

Abstract

This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.
Lingua originaleEnglish
pagine (da-a)576-585
Numero di pagine10
RivistaJournal of Medical Economics
Volume15
DOI
Stato di pubblicazionePubblicato - 2012

Keywords

  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Female
  • Health Care Costs
  • Health Resources
  • Humans
  • Italy
  • Male
  • Quality of Life
  • Quality-Adjusted Life Years
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha

Fingerprint Entra nei temi di ricerca di 'Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy'. Insieme formano una fingerprint unica.

Cita questo